219 related articles for article (PubMed ID: 30542204)
1. A somatic activating NRAS variant associated with kaposiform lymphangiomatosis.
Barclay SF; Inman KW; Luks VL; McIntyre JB; Al-Ibraheemi A; Church AJ; Perez-Atayde AR; Mangray S; Jeng M; Kreimer SR; Walker L; Fishman SJ; Alomari AI; Chaudry G; Trenor Iii CC; Adams D; Kozakewich HPW; Kurek KC
Genet Med; 2019 Jul; 21(7):1517-1524. PubMed ID: 30542204
[TBL] [Abstract][Full Text] [Related]
2. Detection of NRAS mutation in cell-free DNA biological fluids from patients with kaposiform lymphangiomatosis.
Ozeki M; Aoki Y; Nozawa A; Yasue S; Endo S; Hori Y; Matsuoka K; Niihori T; Funayama R; Shirota M; Nakayama K; Fukao T
Orphanet J Rare Dis; 2019 Sep; 14(1):215. PubMed ID: 31511039
[TBL] [Abstract][Full Text] [Related]
3. Treatment of severe Kaposiform lymphangiomatosis positive for NRAS mutation by MEK inhibition.
Chowers G; Abebe-Campino G; Golan H; Vivante A; Greenberger S; Soudack M; Barkai G; Fox-Fisher I; Li D; March M; Battig MR; Hakonarson H; Adams D; Dori Y; Dagan A
Pediatr Res; 2023 Dec; 94(6):1911-1915. PubMed ID: 35246606
[TBL] [Abstract][Full Text] [Related]
4. NRAS
Pastura P; McDaniel CG; Alharbi S; Fox D; Coleman B; Malik P; Adams DM; Le Cras TD
Pediatr Blood Cancer; 2024 Jul; 71(7):e31032. PubMed ID: 38711167
[TBL] [Abstract][Full Text] [Related]
5. Characterization of kaposiform lymphangiomatosis tissue-derived cells.
Nozawa A; Ozeki M; Yasue S; Endo S; Noguchi K; Kanayama T; Tomita H; Aoki Y; Ohnishi H
Pediatr Blood Cancer; 2021 Oct; 68(10):e29086. PubMed ID: 33913609
[TBL] [Abstract][Full Text] [Related]
6. Cellular variant of kaposiform lymphangiomatosis: a report of three cases, expanding the morphologic and molecular genetic spectrum of this rare entity.
Allen-Rhoades W; Al-Ibraheemi A; Kohorst M; Tollefson M; Hull N; Polites S; Folpe AL
Hum Pathol; 2022 Apr; 122():72-81. PubMed ID: 35202617
[TBL] [Abstract][Full Text] [Related]
7. NRAS
Boscolo E; Pastura P; Schrenk S; Goines J; Kang R; Pillis D; Malik P; Le Cras TD
Angiogenesis; 2022 Aug; 25(3):331-342. PubMed ID: 35391614
[TBL] [Abstract][Full Text] [Related]
8. Lymphatic endothelial cell-specific NRAS p.Q61R mutant embryos show abnormal lymphatic vessel morphogenesis.
Nozawa A; Abe T; Niihori T; Ozeki M; Aoki Y; Ohnishi H
Hum Mol Genet; 2024 May; ():. PubMed ID: 38743908
[TBL] [Abstract][Full Text] [Related]
9. Clinical Features and Prognosis of Generalized Lymphatic Anomaly, Kaposiform Lymphangiomatosis, and Gorham-Stout Disease.
Ozeki M; Fujino A; Matsuoka K; Nosaka S; Kuroda T; Fukao T
Pediatr Blood Cancer; 2016 May; 63(5):832-8. PubMed ID: 26806875
[TBL] [Abstract][Full Text] [Related]
10. Kaposiform Lymphangiomatosis in a Male Adolescent: A Clinical Challenge and the Role of Genetics.
Pereira-Nunes J; Madureira M; Dinis A; Barroca H; Lima J; do Bom-Sucesso M
J Investig Med High Impact Case Rep; 2023; 11():23247096231166678. PubMed ID: 37148180
[TBL] [Abstract][Full Text] [Related]
11. Signaling pathways and inhibitors of cells from patients with kaposiform lymphangiomatosis.
Boscolo E; Pastura P; Glaser K; Goines J; Hammill AM; Adams DM; Dickie P; Hsi Dickie B; Le Cras TD
Pediatr Blood Cancer; 2019 Aug; 66(8):e27790. PubMed ID: 31045327
[TBL] [Abstract][Full Text] [Related]
12. Kaposiform lymphangiomatosis: a distinct aggressive lymphatic anomaly.
Croteau SE; Kozakewich HP; Perez-Atayde AR; Fishman SJ; Alomari AI; Chaudry G; Mulliken JB; Trenor CC
J Pediatr; 2014 Feb; 164(2):383-8. PubMed ID: 24252784
[TBL] [Abstract][Full Text] [Related]
13. Kaposiform lymphangiomatosis effectively treated with MEK inhibition.
Foster JB; Li D; March ME; Sheppard SE; Adams DM; Hakonarson H; Dori Y
EMBO Mol Med; 2020 Oct; 12(10):e12324. PubMed ID: 32894644
[TBL] [Abstract][Full Text] [Related]
14. Changes in cell morphology and function induced by the NRAS Q61R mutation in lymphatic endothelial cells.
Yasue S; Ozeki M; Nozawa A; Endo S; Ohnishi H
PLoS One; 2024; 19(5):e0289187. PubMed ID: 38809881
[TBL] [Abstract][Full Text] [Related]
15. Angiopoietins as serum biomarkers for lymphatic anomalies.
Le Cras TD; Mobberley-Schuman PS; Broering M; Fei L; Trenor CC; Adams DM
Angiogenesis; 2017 Feb; 20(1):163-173. PubMed ID: 27990590
[TBL] [Abstract][Full Text] [Related]
16. Imaging features of kaposiform lymphangiomatosis.
Goyal P; Alomari AI; Kozakewich HP; Trenor CC; Perez-Atayde AR; Fishman SJ; Greene AK; Shaikh R; Chaudry G
Pediatr Radiol; 2016 Aug; 46(9):1282-90. PubMed ID: 27053281
[TBL] [Abstract][Full Text] [Related]
17. Complex Lymphatic Anomalies: Report on a Patient Registry Using the Latest Diagnostic Guidelines.
Andreoti TA; Berg S; Holm A; Angerer M; Oberlin M; Foeldi E; Baumgartner I; Niemeyer CM; Rössler J; Kapp FG
Lymphat Res Biol; 2023 Jun; 21(3):230-243. PubMed ID: 36706428
[No Abstract] [Full Text] [Related]
18. Sirolimus in the treatment of kaposiform lymphangiomatosis.
Zhou J; Yang K; Chen S; Ji Y
Orphanet J Rare Dis; 2021 Jun; 16(1):260. PubMed ID: 34103076
[TBL] [Abstract][Full Text] [Related]
19. Potential biomarkers of kaposiform lymphangiomatosis.
Ozeki M; Nozawa A; Kawamoto N; Fujino A; Hirakawa S; Fukao T
Pediatr Blood Cancer; 2019 Sep; 66(9):e27878. PubMed ID: 31207041
[TBL] [Abstract][Full Text] [Related]
20. SP174, NRAS Q61R Mutant-Specific Antibody, Cross-Reacts With KRAS Q61R Mutant Protein in Colorectal Carcinoma.
Lasota J; Kowalik A; Felisiak-Golabek A; Inaguma S; Wang ZF; Pięciak L; Zięba S; Pęksa R; Kopczynski J; Okoń K; Waloszczyk P; Gozdz S; Biernat W; Miettinen M
Arch Pathol Lab Med; 2017 Apr; 141(4):564-568. PubMed ID: 28353383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
